Boers, Ruben http://orcid.org/0000-0002-3377-2897
Boers, Joachim
Tan, Beatrice http://orcid.org/0000-0001-6362-7474
van Leeuwen, Marieke E. http://orcid.org/0000-0002-1481-4844
Wassenaar, Evelyne
Sanchez, Erlantz Gonzalez
Sleddens, Esther
Tenhagen, Yasha http://orcid.org/0000-0002-2319-1247
Mulugeta, Eskeatnaf http://orcid.org/0000-0003-4045-4835
Laven, Joop
Creyghton, Menno
Baarends, Willy
van IJcken, Wilfred F. J. http://orcid.org/0000-0002-0421-8301
Gribnau, Joost http://orcid.org/0000-0001-5645-4691
Article History
Received: 1 July 2021
Accepted: 20 January 2023
First Online: 23 February 2023
Competing interests
: The authors declare no conflicts of interest except for R.B., J.B., W.F.J.v.I. and J.G. who report being shareholders in Methylomics B.V., a commercial company that applies MeD-seq to develop methylation markers for cancer staging.